冻融胚胎移植前血清孕酮水平升高不负面影响生殖结局:一项大型回顾性队列研究
该回顾性队列研究纳入2009年3月至2020年12月间接受激素替代治疗的3183个冻融胚胎移植周期,所有患者移植前血清孕酮≥10.6 ng/mL。结果显示,移植前血清孕酮水平升高(包括≥p90和≥p95)与临床妊娠率、流产率和活产率无显著差异,且在多因素回归分析中未对活产率产生负面影响。
要点
- 移植前血清孕酮中位数为14.39 ng/mL,阴道联合皮下孕酮组水平显著高于单用阴道组。
- 无论同源、整倍体还是异源冻融胚胎移植,阴道单用或联合皮下孕酮的临床妊娠率、流产率和活产率均无差异。
- 血清孕酮≥p90(22.33 ng/mL)与<p90组的活产率分别为43.9%和41.3%,无显著差异。
核心结论
- 在采用阴道或阴道联合皮下孕酮进行人工准备周期的患者中,冻融胚胎移植前血清孕酮水平升高不损害生殖结局。
研究设计与样本
- 回顾性队列研究,纳入2009年3月至2020年12月间接受激素替代治疗的3183个冻融胚胎移植周期,其中同源冻融胚胎移植1360个周期、整倍体冻融胚胎移植1024个周期、异源冻融胚胎移植799个周期。
主要发现
- 移植前血清孕酮中位数(P25;P75)为14.39(12.43-17.49)ng/mL,阴道联合皮下孕酮组为15.96(13.74-21.60)ng/mL,显著高于单用阴道孕酮组的14.09(12.19-16.95)ng/mL。
- 在同源、整倍体和异源冻融胚胎移植各组中,阴道单用与阴道联合皮下孕酮的临床妊娠率、流产率和活产率均无差异。
- 血清孕酮≥p90(22.33 ng/mL)组与<p90组的活产率分别为43.9%和41.3%,无显著差异。
- 血清孕酮≥p90组体重指数低于<p90组(22.62 ± 3.82 vs. 23.32 ± 4.06)。
- 按血清孕酮十分位数分组后,各组活产率无差异;广义相加模型未观察到孕酮水平与活产率之间的关联。
关键数值与推荐
- 所有患者移植前血清孕酮水平均≥10.6 ng/mL。
- 黄体期支持方案为阴道微粒化孕酮200 mg每8小时一次,单用或联合每日皮下注射孕酮25 mg。
- 多因素逻辑回归校正卵母细胞年龄、治疗类型、体重指数、黄体期支持类型和移植胚胎数后,血清孕酮处于p90和p95高水平未对活产率产生负面影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether patients with high-serum progesterone levels before frozen embryo transfer (FET) under hormonal replacement therapy present with worse reproductive outcomes. DESIGN: A cohort retrospective study. SETTING: A university-affiliated fertility center. PATIENT(S): A total of 3,183 FET cycles in patients receiving hormonal replacement therapy between March 2009 and December 2020 were included. The luteal phase was covered with 200 mg per 8 hours of vaginal micronized progesterone either alone or in combination with a daily subcutaneous injection of 25 mg of progesterone. A total of 1,360 cycles corresponded to frozen homologous embryo transfer (ET) (hom-FET), 1,024 were euploid ET (eu-FET) after preimplantation genetic testing for aneuploidies, and 799 cycles were frozen heterologous ET (het-FET). All patients had adequate serum progesterone levels (≥10.6 ng/mL) before the procedure. INTERVENTION(S): Frozen embryo transfer cycles. MAIN OUTCOME MEASURE(S): Clinical pregnancy, miscarriage, and live birth rates (LBRs). RESULTS: Median (P25; P75) serum progesterone level before FET was 14.39 (12.43-17.49) ng/mL. Progesterone levels were significantly higher in the group under vaginal plus subcutaneous progesterone (15.96 [13.74-21.60] vs. 14.09 [12.19-16.95]). No differences in clinical pregnancy, miscarriage, and LBR were observed based on the use of vaginal or vaginal plus subcutaneous progesterone for each of the groups (hom-FET, eu-FET, and het-FET). Live birth rates were comparable among patients in the highest centile of serum progesterone levels (≥p90) (22.33 ng/mL) and the rest of the patients (p<90) (43.9% vs. 41.3%). Patients with progesterone levels ≥p90 presented lower body mass index than those in the lower centiles (<p90) (22.62 ± 3.82 vs. 23.32 ± 4.06). After dividing patients into deciles based on serum progesterone levels, no differences in LBRs were observed among the groups. No association was observed using a generalized additive model between progesterone levels and LBR. A multivariable logistic regression adjusted by oocyte age, type of treatment, body mass index, type of luteal phase support, and the number of embryos transferred was applied for centile 90 and centile 95 of progesterone and showed that serum progesterone in their highest levels did not negatively impact LBR. CONCLUSIONS: Elevated serum progesterone levels before FET do not impair reproductive outcomes in patients receiving artificially prepared cycles with vaginal or vaginal plus subcutaneous progesterone.
引用
- González-Foruria I, García S, Álvarez M, et al. Elevated serum progesterone levels before frozen embryo transfer do not negatively impact reproductive outcomes: a large retrospective cohort study. Fertil Steril. 2023. PMID: 37142050. doi:10.1016/j.fertnstert.2023.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。